Viking Therapeutics reports results from Phase 2b clinical trial of VK2809
Viking Therapeutics (VKTX) announced that final results from the company’s Phase 2b clinical trial of VK2809, the company’s novel ...
Investing10h
After-hours movers: Dolby Laboratories, Powell Industries, Keysight Technologies
Dolby Laboratories (NYSE: DLB) rose 11% after it reported fourth quarter results that beat analysts' estimates on the bottom line. On a non-GAAP basis, f ...
Seeking Alpha11h
Viking phase 2b study of NASH candidate hits primary endpoint
A phase 2b trial of Viking Therapeutics' (NASDAQ:VKTX) VK2809 found that those on the medicine saw statistically significant ...
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
Viking to present data from Phase 2b VOYAGE study in late breaker presentation
Viking Therapeutics (VKTX) announced that results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective ...